Home > Journals > Minerva Pediatrica > Past Issues > Minerva Pediatrica 2017 October;69(5) > Minerva Pediatrica 2017 October;69(5):434-43

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Pediatrica 2017 October;69(5):434-43

DOI: 10.23736/S0026-4946.17.04976-3

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Insulin sensitizers in adolescents with polycystic ovary syndrome

Trang N. LE 1, 2 , Edmond P. WICKHAM 3rd 1, 2, John E. NESTLER 1

1 Division of Endocrinology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA; 2 Division of Pediatric Endocrinology, Children’s Hospital of Richmond, Virginia Commonwealth University, Richmond, VA, USA


PDF


Polycystic ovary syndrome (PCOS) is the most common disorder of androgen excess in women of reproductive age. The diagnosis of PCOS can be more challenging in adolescents than in adult women given significant overlap between normal puberty and the signs of PCOS, including acne, menstrual irregularity, and polycystic ovarian morphology. Optimal treatments for adult women with PCOS vary depending on patient risk factors and reproductive goals, but mainly include hormonal contraception and insulin sensitizers. There is continued interest in targeting the intrinsic insulin resistance that contributes to metabolic and hormonal derangements associated with PCOS. The vast majority of published data on insulin sensitizing PCOS treatments are reported in adult women; these have included weight loss, metformin, thiazolidinediones, and the inositols. Furthermore, there is also a small but growing body of evidence in support of the use of insulin sensitizers in adolescents, with or without oral contraceptives. Discussion of the available treatments, including benefits, potential side effects, and incorporation of patient and family preferences is critical in developing a plan of care aimed at achieving patient-important improvements in PCOS signs and symptoms while addressing the longer-term cardiometabolic risks associated with the syndrome.


KEY WORDS: Polycystic ovary syndrome - Adolescent - Insulin

top of page